Article in Clinical transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 2 institutions in 1 country.
Kathleen YuDepartment of Medicine, Division of Nephrology, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0001-5015-4110
Syed A HusainDepartment of Medicine, Division of Nephrology, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0002-1823-0117
Kristen KingDepartment of Medicine, Division of Nephrology, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0002-7920-7615
Jacob S StevensDepartment of Medicine, Division of Nephrology, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0001-9614-1673
Chirag R ParikhDivision of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-9051-7385
Sumit MohanDepartment of Medicine, Division of Nephrology, Columbia University Medical Center, New York, New York, USA.ORCID 0000-0002-5305-9685
Columbia University Irving Medical Center · USJohns Hopkins University · US
Funding
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Institutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft OutcomesR01DK093770 · NIDDK · YALE UNIVERSITY · PI Chirag R Parikh · 2012 to 2026
$9.5M
Continuous Therapeutic Drug Monitoring of Antibiotics in CRRTR01DK126739 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOHAN, SUMIT · 2021 to 2024
$2.8M
India - Factors of CKDu in Uddanam Study (India-FOCUS)U01DK130058 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Vivekanand Jha, Sumit Mohan · 2021 to 2026
$2.6M
5/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical CenterU01DK116066 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Sumit Mohan, Deirdre Sawinski · 2017 to 2026
$2.5M
Leveraging Clinical Trials of Diabetic Kidney Disease to Advance BiomarkersU01DK106962 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G, PARIKH, CHIRAG R · 2015 to 2019
$1.3M
Identifying and exploring solutions to the ethical challenges of ApoL1 testing of donors with recent African ancestry through mixed methods research with stakeholdersR01MD014161 · NIMHD · WASHINGTON UNIVERSITY · PI DUBOIS, JAMES M, MOHAN, SUMIT · 2019 to 2021
$1.2M
Increasing Minority Population Awareness through Community Teaching for Improved Organ Donation (IMPACT for Improved Organ Donation)R01DK114893 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOHAN, SUMIT · 2017 to 2021
$1.2M
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)UH3DK114866 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI PARIKH, CHIRAG R · 2019 to 2021
$900k
Using Decision Making Science to Optimize Deceased Donor Kidney AllocationK23DK133729 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUSAIN, SYED ALI · 2022 to 2025
backgroundAcute kidney injury (AKI) is common in deceased organ donors and is associated with high rates of kidney discard by transplant centers. High discard rates may consequently drive nonprocurement of these kidneys by organ procurement organizations. We aimed to study the relationship between donor AKI and kidney nonprocurement.
methodsUsing U.S. registry data, we identified donors with at least one organ recovered from 2008 to 2018. We compared characteristics of donors with no kidneys procured across AKI stages, and used multivariable logistic regression to evaluate the relationship between AKI severity and kidney nonprocurement.
resultsOverall 14 543 kidneys from 7620 donors were not procured, among which 93% were from donors with AKI. For 6945 donors with no kidneys procured but an extrarenal organ recovered, most had stage 3 (51%), followed by stage 1 (27%) and stage 2 AKI (15%). Nonprocured stage 3 donors were the youngest and had the lowest Kidney Donor Risk Index of all nonprocured donors. Adjusted odds of kidney nonprocurement were 1.14 (95%CI 1.02-1.27) for stage 1, 1.25 (95%CI 1.12-1.41) for stage 2, and 10.37 (95%CI 9.30-11.56) for stage 3 donors, compared to non-AKI donors. Among donors with minimum creatinine <1.5 mg/dl, stage 2 and 3 AKI were still associated with significantly higher odds of nonprocurement.
conclusionsAKI severity is a strong risk factor for kidney nonprocurement. Efforts to address the organ shortage should focus on encouraging procurement and utilization of kidneys from deceased donors with severe AKI, given the large and rising prevalence of donor AKI and excellent transplant outcomes with these kidneys.
Indexed as
Acute Kidney InjuryKidney TransplantationTissue and Organ ProcurementDonor SelectionGraft SurvivalHumansKidneyTissue Donorsacute kidney injurycreatininedeceased donordonor selectionkidney transplantationorgan donationorgan procurement
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Kidney nonprocurement in deceased donors with acute kidney injury. · full record | OpenQuestion